Bristol's Once-daily Sprycel Faces Off Against Novartis' Tasigna After Clearance In First-line Leukemia
Tasigna sales were up by almost 100% in one quarter with first-line clearance.
Tasigna sales were up by almost 100% in one quarter with first-line clearance.